Frequently Asked Questions:
- What is telikibart?
Telikibart (GR1802) is an investigational fully human monoclonal antibody targeting IL-4Rα, blocking IL-4 and IL-13 signaling, with an Fc region engineered to eliminate antibody-dependent cell-mediated cytotoxicity.
- What did the phase 3 telikibart trial show?
In 450 adults with moderate to severe atopic dermatitis, telikibart achieved EASI-75 in 69.6% of patients versus 22.5% with placebo at week 16, and in more than 94% of patients by Week 52.
Nearly 70% of adults with moderate to severe atopic dermatitis treated with telikibart reached EASI-75 at Week 16, roughly triple the placebo rate, according to phase 3 results presented as a late-breaking abstract at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria. By Week 52, more than 9 in 10 patients on continuous or crossover therapy achieved this threshold.¹
Telikibart, also known as GR1802, is a fully human monoclonal antibody against the interleukin 4 receptor alpha (IL-4Rα) subunit, blocking both IL-4 and IL-13 signaling. Its Fc region carries 3 engineered mutations designed to eliminate antibody-dependent cell-mediated cytotoxicity, a modification the investigators linked to a favorable safety profile.¹
The trial was conducted across dozens of dermatology centers in China, with authors led by Shangshang Wang of Huashan Hospital, Fudan University, in Shanghai. A prior phase 2 study had shown early efficacy signals in this population.¹
How Was the Telikibart Phase 3 Trial Designed?
The randomized, placebo-controlled trial (NCT06216392) enrolled 450 adults between January 2024 and August 2025, assigning them 2:1 to telikibart (n = 299) or placebo (n = 151). Patients received a 600 mg loading dose followed by 300 mg every 2 weeks during a 16-week induction period.¹˒²
All participants then received telikibart 300 mg every 2 weeks through Week 52, with placebo recipients given a 600 mg loading dose at crossover.¹
Coprimary end points at the 16 week mark were EASI-75 and Investigator's Global Assessment (IGA) 0/1 with at least a 2-point improvement from baseline.¹
What Efficacy Did Telikibart Show at Weeks 16 and 52?
At Week 16, 69.6% of patients receiving telikibart achieved EASI-75 compared with 22.5% receiving placebo (difference, 47.1%; 95% CI, 38.62-55.50; P < .0001). IGA 0/1 response reached 33.1% versus 6.6% (difference, 26.5%; 95% CI, 19.86-33.15; P < .0001).¹
Telikibart also outperformed placebo on EASI-90, a reduction of at least 4 points in weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) score, and least squares mean improvement in Dermatology Life Quality Index (all P < .0001).¹